Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
The price of Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $13.53 in the last session, down -6.95% from day before closing price of $14.54. In other words, the price has decreased by -$6.95 from its previous closing price. On the day, 0.75 million shares were traded. MLYS stock price reached its highest trading level at $14.7 during the session, while it also had its lowest trading level at $13.44.
Ratios:
We take a closer look at MLYS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 26.48 and its Current Ratio is at 26.48. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 13 ’25 when Rodman David Malcom sold 11,366 shares for $14.60 per share. The transaction valued at 165,931 led to the insider holds 101,651 shares of the business.
Rodman David Malcom bought 11,366 shares of MLYS for $165,931 on Jun 13 ’25. On May 14 ’25, another insider, Rodman David Malcom, who serves as the Chief Medical Officer of the company, sold 11,366 shares for $15.29 each. As a result, the insider received 173,774 and left with 106,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 881821760 and an Enterprise Value of 538795648.
Stock Price History:
The Beta on a monthly basis for MLYS is -0.31, which has changed by 0.049650908 over the last 52 weeks, in comparison to a change of 0.11708844 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $18.38, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -9.06%, while the 200-Day Moving Average is calculated to be 4.08%.
Shares Statistics:
According to the various share statistics, MLYS traded on average about 862.71K shares per day over the past 3-months and 854520 shares per day over the past 10 days. A total of 64.88M shares are outstanding, with a floating share count of 40.61M. Insiders hold about 37.70% of the company’s shares, while institutions hold 65.84% stake in the company. Shares short for MLYS as of 1749772800 were 6168786 with a Short Ratio of 7.15, compared to 1747267200 on 7206718. Therefore, it implies a Short% of Shares Outstanding of 6168786 and a Short% of Float of 12.509999999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Mineralys Therapeutics Inc (MLYS) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.73, with high estimates of -$0.52 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$2.36 and -$3.59 for the fiscal current year, implying an average EPS of -$2.93. EPS for the following year is -$3.17, with 7.0 analysts recommending between -$2.15 and -$4.53.
